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Abstract: In an attempt to find a new class of antimicrobial agents, a series of thiazole derivatives containing furan moiety 3, 7, 8a,b, 10a-c and 
12 were prepared via the reaction of 2-cyano-N-(furan-2-ylmethyl)acetamide (1) with phenyl isothiocyanate and α-halocarbonyl compounds. 
Also, many bithiazolidinone and pyranothiazole derivatives were synthesized through interaction of thiazolidinone 7 with appropriate 
electrophilic reagents. These compounds were screened for their antibacterial and antifungal activity. Among the synthesized compounds, 
thiazole derivatives 23a and 23b were equipotent to gentamycin against K. pneumonia (MIC 0.49 µg/mL), and showed in vitro antifungal activity 
equipotent to amphotericin B versus A. fumigatus (MIC 0.98 µg/mL), A. clavatus (MIC 0.98 µg/mL) and G. candidium (MIC 0.49 µg/mL). Also, 
bithiazolidinones 14 and 15 were equipotent to amphotericin B in inhibiting the growth of A. clavatus (MIC 0.98 µg/mL) and G. candidium (MIC 
0.49 µg/mL). Structures of the newly synthesized compounds were established by elemental analysis and spectral data. 
 





ESPITE a large number of antibiotics and chemo-
therapeutics available for medical use, the emerging 
resistance to old and new antibiotics has created a 
substantial need for new classes of antimicrobial agents. A 
potential approach to overcome the problem of antibiotic 
resistance is to design innovative agents with different 
modes of action, so that no cross resistance with present 
drugs can occur.[1] 
 Thiazoles are a familiar group of heterocyclic 
compounds possessing a wide variety of biological 
activities, and their usefulness as medicines are well 
established. This later is also an integral part of all the 
available penicillins, which have revolutionized the therapy 
of bacterial diseases.[2] Thiazoles have also attracted 
continuing interest because of their varied biological 
activities,[3] which have found applications in the treatment 
of allergies,[4] hypertension,[5] inflammation,[6] schizophre-
nia,[7] microbial infections,[8,9] HIV infections,[10] hypnotics[11] 
and for the treatment of pain.[12] They have been also 
used as fibrinogen receptor antagonists with antithromb-
otic activity[13] and as new inhibitors of bacterial DNA 
gyrase B.[14] 
 Moreover, many biologically important derivatives 
of furan substituted at 2- and 5-positions are frequently 
observed in nature show broad-spectrum phytocidal, 
antibacterial and insecticidal activities[15,16] and exhibit 
pharmacological properties which serves as anti-
depressant and anti-inflammatory agents.[17,18] 
 In view of the above-mentioned findings, and as a 
continuation of our effort to identify new candidates,[19−26] 
which are crucial in designing new, potent, selective, and 
less toxic antimicrobial agents, its report herein the 
synthesis and antimicrobial evaluation of some novel 
structure hybrids incorporating both the thiazole ring 
system with furan moiety. This combination was suggested 
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hybridization and structure variation on the anticipated 
biological activities, hoping to add some synergistic 
biological significance to the target molecules. The target 
compounds were rationalized so as to comprise some 
pharmacophores that are believed to be responsible for the 
biological activity of some relevant chemotherapeutic such 
as the carboxamido, amino and cyano groups functio-
nalities. The substitution pattern of the thiazole ring was 
carefully selected in order to confer different electronic 
environment to the molecules. 
 
RESULTS AND DISCUSSION 
Chemistry 
The starting compound 2-cyano-N-(furan-2-ylmethyl)ace-
tamide (1) was readily available from the solvent-free 
reaction of furan-2-ylmethanamine with an excess 
amount of ethyl cyanoacetate under fusion condition,[27] 
(Scheme 1). 
 The active methylene moiety of 2-cyano-N-(furan-2-
ylmethyl)acetamide (1) was allowed to react with phenyl 
isothiocyanate in dimethylformamide in the presence of an 
equimolar amount of potassium hydroxide yielded the non-
isolable intermediate potassium sulphide salt 2, which 
reacted in situ with chloroacetonitrile to afford the novel 4-
aminothiazole derivative 3 rather than thiophene structure 
4. The reaction product 3 was confirmed on the basis of 
elemental analysis and spectral data. The IR spectrum of 3 
showed absorption bands at 3423, 3308, 3110, 2184 and 
1637 cm−1 assignable for NH2, NH, CN and carboxamide 
groups, respectively. While its 1H NMR spectrum showed 
doublet and singlet signals at δ 4.27, 7.16 ppm 
characteristic for CH2 and thiazole-H5 protons, doublet and 
triplet signals at δ 6.14, 6.34 ppm can be assigned to furan 
protons, in addition to singlet and triplet signals at δ 8.22, 
10.08 ppm for NH2 and NH protons, respectively. Also, it 
has been found that, the in situ reaction of 2 with 2-chloro-
N-phenylacetamide afforded thiazolidin-4-one 7 rather 
than the expected thiophene 6. The formation of 
thiazolidin-4-one 7 may be rationalized through the first S-
alkylation to form non-isolable intermediate 5 followed by 
nucleophilic addition of NH group to the amidic carbonyl 
with elimination of aniline. 1H NMR spectrum of compound 
7 was characterized by the presence of a singlet signal at δ 
3.92 ppm for thiazole methylene protons. 13C NMR of 
compound 7 revealed signals at δ 34.70 (C5 of thiazole), 
36.32 (CH2), 165.95, 167.77 (C4, C2 of thiazole), in addition 
to, signals at 107.35, 110.85, 138.39 and 142.37 ppm that 
are characteristic for furan carbons. The structure of the 
isolated product 7 was elucidated also, by independent 
synthesis via treatment of the intermediate 2 with ethyl 
chloroacetate. Cycloalkylation of non-isolable salt 2 with 
either ethyl α-chloropropionate or ethyl α-bromobutyrate 
produced in each case, a single product. The reaction 
products can be formulated as thiazolidin-4-one derivatives 
8a and 8b, evidence for assigned structures being provided 
by analytical and spectroscopic data. For example, the IR 
spectrum of compound 8a showed the appearance of 
absorption band at 3326, 2203, 1733 and 1646 cm−1 
corresponding to the NH, CN, (C=O; thiazolidinone) and 
carboxamide groups, respectively. The 1H NMR spectrum of 
compound 8a exhibited signals at δ 1.56 (d, 3H, CH3), 4.25 
(q, 1H, CH), 4.33 (d, 2H, CH2) with triplet signal at δ 7.95 
ppm for the amide group proton. The formation of 8 was 
assumed to proceed via an initial alkylation followed by 
intramolecular cyclization with ethanol elimination 
(Scheme 2). 
 Next, treatment of the intermediate 2, formed in situ 
under the same reaction condition, with α-halogenated 
compounds 9 produced in each case a single product 
identified as 4-methylthiazole derivatives 10 instead of the 
thiophene derivative 11 (Scheme 3). The structure of the 4-
methylthiazoles 10 was established by analytical and 
 
Scheme 1. Synthesis of 2-cyano-N-(furan-2-ylmethyl)aceta-
mide. 
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spectroscopic data. The IR spectrum of compound 10a 
showed the appearance of absorption band at 3367, 2170 
and 1646 cm−1 corresponding to the imino, nitrile and 
carboxamide groups, respectively. The 1H NMR spectrum of 
compound 10b was characteristic by the presence of 
singlet signals at δ 2.09, 2.30 for 2CH3 with triplet signal at 
δ 9.67 ppm for NH protons. 13C NMR of compound 10b 
revealed signals at δ 14.31, 29.95 (2CH3), 36.10 (CH2), 
115.06, 145.35, 170.21 (thiazole-carbons), in addition to 
two singlet at δ 163.96 and 165.22 ppm (2C=O). Similarly, 
cyclocondensation of the intermediate salt 2 with 2-bromo-
1-(4-nitrophenyl)ethanone at room temperature afforded 
the corresponding 2,3-dihydrothiazole derivative 12 
(Scheme 3). The structure of the latter product was 
confirmed by the presence of singlet signal at δ 6.87 ppm 
assignable for thiazole-H5 in 1H NMR spectrum. 
 To investigate the structure reactivity relationship 
with respect to antimicrobial properties, the reactivity of 4-
thiazolidinone 7 toward some electrophilic reagents was 
investigated and bithiazolidinone derivatives were 
obtained. Thus, the non-isolable potassium sulphide salt 13 
was achieved by the nucleophilic addition of active 
methylene group in 4-thiazolidinone 7 to phenyl 
isothiocyanate in dry dimethylformamide at room 
temperature in the presence of potassium hydroxide 
(Scheme 4). Cycloalkylation of non-isolable salt 13 with 
ethyl chloroacetate and/or ethyl α-bromobutyrate at room 
temperature gave bithiazolidinone derivatives 14 and 15. 
13C NMR of compound 14 revealed signals at δ 31.65 (CH2), 
106.60 (thiazole-C5`), 163.63, 166.12 (thiazole-C4, C4`), in 
addition to singlet signal at 173.30 ppm (C=O). 
Furthermore, the Knoevenagel condensation of thiazolidin-
4-one 7 with terephthalaldehyde in ethanolic piperidine 
solution under reflux conditions afforded the 
corresponding bithiazolidinone derivative 16 (Scheme 4). 
 In addition, pyrano[2,3-d] thiazoles are useful in the 
treatment of diseases such as diabetes, obesity, 
hyperlipidemia, and atherosclerotic diseases.[28] They are 
also known to show bactericidal, fungicidal and 
molluscicidal activities.[29,30] Therefore, pyrano[2,3-
d]thiazole of type 19 was obtained by reaction between 
equimolecular amounts of compound 7 and chalcone 
derivative 17 in the presence of a catalytic amount of 
piperidine. The structure formula of compound 19 resulting 
from this reaction has been confirmed using elemental 
analyses and spectral methods. 1H NMR spectrum of 
compound 19 showed a new two doublet and singlet 
signals at δ 3.43, 4.94, 3.84 ppm corresponding to H4, H5 
of pyran and methoxy protons, in addition to triplet signal 
at 8.20 ppm assignable for NH proton. The formation of 19 
was assumed to proceed via Micheal addition of the active 
methylene to the α,β-unsaturated ketone 17 to yield the 
Micheal adduct 18 followed by intramolecular cyclization 
with elimination of water. In contrast to the anticipated 
formation of pyrano[2,3-d]thiazole derivative 19, the 
reaction of 7 with α-cinnamonitriles 20a,b in refluxing 
ethanol and in the presence of a catalytic amount of 
piperidine, the corresponding benzyilidine thiazolidinone 
 
Scheme 3. Synthetic route to thiazoles. 
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derivative 23 was obtained. The formation of this 
compound was assumed to proceed via retro Michael 
addition through the elimination of malononitrile from the 
non-isolable adduct 22. The structure of the isolated 
products 23a,b were elucidated on the basis of their 
spectral data (IR, MS and 1H NMR) and also, by independent 
synthesis via reaction of the thiazolidinone 7 with benz-
aldehyde derivatives 24 (Scheme 5). 
Antimicrobial Evaluation 
Fourteen of the newly synthesized target compounds were 
evaluated for their in vitro antibacterial activity against 
Staphylococcus aureus (RCMB 010027), Staphylococcus 
epidermidis (RCMB 010024) and Bacillis subitilis (RCMB 
010063) as examples of Gram-positive bacteria and 
Pseudomonas aeruginosa (RCMB 010043), Proteous 
vulgaris (RCMB 010085) and Klebsiella pneumonia (RCMB 
010093) as examples of Gram-negative bacteria. They were 
also evaluated for their in vitro antifungal potential against 
Aspergillus fumigatus, Aspergillus clavatus and Geotricum 
candidium fungal strain. 
 Agar-diffusion method [31] was used for the deter-
mination of the preliminary antibacterial and antifungal 
activity. Ampicillin, gentamycin and amphotericin B were 
used as reference drugs. The results were recorded for each 
tested compound as the average diameter of inhibition 
zones (IZ) of bacterial or fungal growth around the disks in 
mm. The minimum inhibitory concentration (MIC) mea-
surement was determined for compounds with significant 
growth inhibition zones using twofold serial dilution 
method.[32] The MIC (µg/mL) and inhibition zone diameters 
values are presented in Table 1. The results depicted in 
Table 1 revealed that most of tested compounds displayed 
variable inhibitory effects on the growth of the tested 
Gram-positive and Gram-negative bacterial strains and also 
against antifungal strains. 
 Regarding the structure reactivity relationship 
between the thiazoles and antibacterial activities, the 
Scheme 5. Synthetic route to pyrano[2,3-d]thiazole. 
 
 
Table 1. Antimicrobial inhibition zone in mm and minimal inhibitory concentrations (MIC, µg/ml, between brackets) of some 
new synthesized compounds 
Compounds no. Gram-positive bacteria Gram-negative bacteria Fungi 
 S. aureus S. epidermidis B. subitilis P. aeruginosa P. vulgaris K. pneumonia A. fumigatus A. clavatus G. candidium 
3 14.3 16.2 16.2          NA* 14.2 14.8 14.6 14.9 15.7 
7 15.3 17.4 17.9 NA 13.6 15.4 12.3 14.2 14.9 
8a 19.6 20.1 21.2 NA 17.6 19.1 17.2 19.6 20.9 
8b 18.1 20.2 20.9 NA 16.2 19.9 16.3 18.2 20.3 
10a 20.6 22.3 20.7 NA 16.3 18.1 16.3 19.2 19.6 
10b 20.6 22.3 23.1 NA 21.2 23.6 18.6 19.2 20.9 
10c 17.4 17.9 19.2 NA 16.3 17.2 13.3 15.2 17.3 
12 20.2(3.9) 21.4(1.95) 23.6(0.98) NA 18.3(7.81) 22.4(0.98) 18.2(7.81) 21.4(1.95) 23.2(0.98) 
14 21.2(1.95) 21.9(0.98) 23.7(0.48) NA 19.2(3.9) 23.3(0.98) 20.3(3.9) 22.3(0.98) 23.6(0.49) 
15 21.8(1.95) 22.7(0.98) 24.1(0.48) NA 20.1(3.9) 23.1(0.98) 19.7(3.9) 22.7(0.98) 23.8 (0.49) 
16 20.3(3.9) 21.2(1.95) 22.9(0.98) NA 20.3(3.9) 22.4(0.98) 20.1(3.9) 21.9(0.98) 23.5(0.98) 
19 16.2 17.5 18.1 NA 14.2 15.7 14.3 16.2 15.4 
23a 21.4(1.95) 22.3(0.98) 23.6(0.49) NA 21.4(1.95) 23.6(0.49) 22.3(0.98) 22.7(0.98) 23.9(0.98) 
23b 20.3(1.93) 19.2(0.98) 22.4(0.49)  NA 19.3(1.95) 21.3(0.49) 21.1(0.98) 20.7(0.98) 22.9(0.98) 
Ampicillin 28.9(0.24) 25.4(0.49) (0.24)36.6      NA*   NT NT NT NT NT 
Gentamycin   NT* NT NT  (3.9)19.9  25.4(0.98) 26.3(0.49) NT NT NT 
Amphotericin B NT NT NT  NT  NT NT 23.7(0.98) 21.9(0.98) 25.4(0.49) 
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results showed that thiazole benzyilidine derivatives 23a, 
23b and bithiazolodinone derivatives 14−16 were the most 
active among the synthesized compounds (Figures 1 and 2). 
Thiazoles 10b, 10c and 12 containing electron withdrawing 
groups such as COCH3, CO2C2H5 and NO2 recorded 
moderate to good activity. In this view, compounds 23a and 
23b were equipotent to gentamycin against K. pneumonia 
(MIC 0.49 µg/mL), while their activity were 50 % lower than 
both gentamycin and ampicillin in inhibiting the growth of 
P. vulgaris (MIC 1.95 µg/mL), S. epidermidis (MIC 0.98 
µg/mL) and B. subitilis (MIC 0.49 µg/mL). Bithiazolodinone 
derivatives 14 and 15 showed 50 % of the activity of 
ampicillin and gentamycin against S. epidermidis (MIC 0.98 
µg/mL), B. subitilis (MIC 0.49 µg/mL). Bithiazolodinone 20 
showed relatively good growth inhibitory profiles against K. 
pneumonia (MIC 0.98 µg/mL) which was about 50 % of the 
activity of gentamycin. The 4-nitrophenylthiazole 12 
showed relatively good growth inhibitory profiles against B. 
subitilis (MIC 0.98 µg/mL) and K. pneumonia (MIC 0.98 
µg/mL), which was about 50 % of the activity of ampicillin 
and gentamycin. Concerning the antibacterial activity of 
the compounds 3, 7, 8a, 8b, 10a, 10c and 19 showed weak 
activities against the tested Gram-positive and Gram-
negative bacteria. Unfortunately, all the tested compounds 
were completely inactive toward P. aeruginosa (RCMB 
010043) compared to gentamycin. Gram negative bacteria 
have a relatively thin cell wall constituted by few layers of 
peptidoglycan surrounded by a second lipid membrane 
containing lipopolysaccharides and lipoproteins. These 
differences in cell wall structure can produce differences in 
antibacterial susceptibility and some antibiotics are 
ineffective against Gram-negative pathogens. [33–35] 
 Regarding the activity of thiazoles incorporating 
furan moiety versus antifungal strains, thiazole benzyildine 
23a and 23b showed in vitro antifungal activity equipotent 
to amphotericin B against A. fumigatus (MIC 0.98 µg/mL), 
A. clavatus (MIC 0.98 µg/mL) and G. candidium (MIC 0.49 
µg/mL). Bithiazolidinones 14 and 15 were equipotent to 
amphote-ricin B in inhibiting the growth of A. clavatus (MIC 
0.98 µg/mL) and G. candidium (MIC 0.49 µg/mL). But their 
activities were 25 % of amphote-ricin B against A. fumigatus 
(MIC 3.9 µg/mL). indeed, Bithiazolidinones 16 displayed 
equipotent activity to amphotericin B versus A. clavatus 
(MIC 0.98 µg/mL) while its activity was 50 % lower than G. 
candidium (MIC 0.98 µg/mL) compared to amphotericin B. 
4-Nitrophenylthiazole 12 showed relatively good growth 
inhibitory profiles versus A. clavatus (MIC 1.95 µg/mL) and 
G. candidium (MIC 0.98 µg/mL) which was about 50 % of 
the activity of amphotericin B. Other synthesized 
compounds showed weak to moderate activity against 
antifungal strains (Figure 3). 
 
CONCLUSION 
The objective of the present study was to synthesize and 
investigate the antimicrobial activities of some new 
thiazoles incorporating furan moiety with the hope of 
discovering new structure leads serving as potent 
antimicrobial agents. Our aim has been verified by the 
synthesis of thiazole, bithiazoles, thiazole benzyilidine and 
pyranothiazole derivatives. It is worth mentioning that, 
synthesis of thiazole derivative containing electron 
withdrawing groups such as 10b, 10c and 12 exhibited good 
antimicrobial activity. The best antimicrobial activity was 







































Figure 1. Antibacterial activity of the synthesized com-
pounds against Gram-positive bacteria. 
 






































Figure 2. Antibacterial activity of the synthesized 
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observed when 4-thiazoledinone 7 was converted into 




All the melting points are uncorrected. IR (KBr) spectra 
were measured on Shimadzu 440 spectrometer; 1H NMR 
and 13C NMR spectra were obtained in DMSO on a Varian 
Gemini 300 MHz spectrometer using TMS as internal 
standard. The chemical shifts are reported as δppm units. 
Mass spectra were obtained on GCMS\QP 1000 Ex mass 
spectrometer at 70 ev. Elemental analyses were carried out 
at the Department of Chemistry, Faculty of Science, Cairo 
University, Egypt. Microbiology screening was carried out 
in the Regional Center for Microbiology and Biotechnology 
(RCMB), Antimicrobial unit test organisms, Al-azhr 
University, Cairo, Egypt. 
General procedure for the preparation 
of compounds 3, 7, 8a,b, 10a–c, 12, 14 
and 15: 
To suspension of finely powdered potassium hydroxide 
(0.01 mol) in dry dimethylformamide (20 mL) the active 
methylene compound (1 and/or 7, 0.01 mol) and then the 
phenyl isothiocyanate (0.01 mol) were added in portions. 
The reaction mixture was stirred at room temperature for 
1 h and then treated with α-halogenated compound (0.01 
mol) and left at room temperature for 2 h; then it was 
poured into ice/water and acidified with 0.1 M HCl at pH 3–
4. The resulting precipitate was filtered off, dried, and 




Brown crystals (AcOH), Yield (50 %), m.p. 229–230ºC; IR 
(KBr) vmax/ cm−1: 3423, 3308, 3110 (NH2/NH), 3058 (arom. 
CH), 2184 (C≡N) and 1637 (C=O; amide); 1H NMR (DMSO-
d6) δ/ppm: 4.27 (d, 2H, CH2-NH, J = 6 Hz), 6.14 (d, 1H, furan-
H3, J = 3 Hz), 6.34 (t, H, furan-H4, J = 3 Hz), 7.16 (s, 1H, 
thiazole-H5), 7.30-7.60 (m, 6H, Ar-H + furan-H5), 8.22 (s, 
2H, NH2), 10.08 (t, 1H, O=C-NH-CH2, J = 6 Hz ). MS (El, 70 ev) 
m/z (%): 338 (M+, 55), 309 (15.2), 242 (35), 215 (39.7), 135 
(72.5), 64 (100) 51 (34.3). Anal. Calcd. for C17H14N4O2S 
(338.38): C, 60.34; H, 4.17; N, 16.56. Found: C, 60.14; H, 




White crystals (EtOH), Yield (80 %), m.p. 108–110 ºC; IR 
(KBr) vmax/cm−1: 3339 (NH), 3036 (arom. CH), 2206 (C≡N), 
1719 (C=O; thiazoldinone) and 1645 (C=O; amide); 1H NMR 
(DMSO-d6) δ/ppm: 3.92 (s, 2H, CH2-thiazole), 4.27 (d, 2H, 
CH2-NH, J = 6 Hz), 6.14 (d, 1H, furan-H3, J = 3 Hz), 6.36 (t, H, 
furan-H4, J = 3 Hz ), 7.23−8.17 (m, 6H, Ar-H + furan-H5), 8.17 
(t, 1H, O=C-NH-CH2, J = 6 Hz); 13C NMR (DMSO-d6) δ/ppm: 
34.70 (thiazole-C5), 36.32 (CH2), 80.90 (C-CN), 107.35, 
110.58, 138.39, 142.37 (furan-C), 124.40, 127.0, 128.20, 
129.72, 129.87 (Ar-C), 152.63 (CN), 165.95, 167.77 
(thiazole-C4, C2), 173.85 (C=O). MS (El, 70 ev) m/z (%): 339 
(M+, 70), 310 (9.2), 298 (18), 265 (27), 236 (22.3), 96 (37.8), 
81 (100) 53 (38.3). Anal. Calcd. for C17H13N3O3S (339.37): C, 




White crystals (AcOH), Yield (60 %), m.p. 190−192 ºC; IR 
(KBr) vmax/ cm-1: 3326 (NH), 3060 (arom. CH), 2915 (aliph. 
CH), 2203 (C≡N), 1733 (C=O; thiazoldinone) and 1646 (C=O; 
amide); 1H NMR (DMSO-d6) δ/ppm: 1.56 (d, 3H, CH3, J = 9 
Hz), 4.25 (q, 1H, CH, J = 9 Hz), 4.33 (d, 2H, CH2-NH, J = 6 Hz), 
6.16 (d, 1H, furan-H3, J = 3 Hz), 6.35 (t, 1H, furan-H4, J = 3 
Hz), 7.38−7.51 (m, 6H, Ar-H + furan-H5), 7.95 (t, 1H, O=C-
NH-CH2, J = 6 Hz). MS (El, 70 ev) m/z (%): 353(M+, 67), 248 
(33.2), 229 (58.5), 203 (17), 142 (22.3), 77(100) 53 (65.3). 
Anal. Calcd. for C18H15N3O3S (353.39): C, 61.18; H, 4.28; N, 




White crystals (AcOH), Yield (55 %), m.p. 199–200 ºC; IR 
(KBr) vmax/cm−1: 3321 (NH), 3040 (arom. CH), 2916 (aliph. 
CH), 2203 (C≡N), 1732 (C=O; thiazoldinone) and 1646 (C=O; 
amide); 1H NMR (DMSO-d6) δ/ppm: 1.03 (t, 3H, CH3, J = 6 
Hz), 1.96 (p, 2H, CH2, J = 6 Hz), 4.19 (t, 1H, CH, J = 6 Hz), 4.27 









































 M. A. SALEM: Syntesis of New Potential Antimicrobial Agents 13 
 




(d, 2H, CH2-NH, J = 6 Hz), 6.17 (d, 1H, furan-H3, J = 3 Hz), 
6.35 (t, 1H, furan-H4, J = 3 Hz), 7.35−7.51 (m, 6H, Ar-H + 
furan-H5), 7.94 (t, 1H, O=C-NH-CH2, J = 6 Hz). MS (El, 70 ev) 
m/z (%): 367(M+, 87), 338 (7), 271 (37.2), 265 (5.5), 243 
(21.5), 217 (12), 96 (50.3), 80 (100), 64 (82), 53 (25). Anal. 
Calcd. for C19H17N3O3S (367.42): C, 62.11; H, 4.66; N, 11.44. 




White powder (EtOH), Yield (70 %), m.p. 240−241 ºC; IR 
(KBr) vmax/cm−1: 3376 (NH), 3046 (arom. CH), 2926 (aliph. 
CH), 2170 (C≡N) and 1646 (C=O; amide); 1H NMR (DMSO-d6) 
δ/ppm: 1.80 (s, 3H, CH3), 4.29 (d, 2H, CH2-NH, J = 6 Hz), 6.12 
(d, 1H, furan-H3, J = 3 Hz), 6.33 (t, 1H, furan-H4, J = 3 Hz), 
6.80 (s, 1H, thiazole-H5), 7.12–7.56 (m, 7H, Ar-H + furan-H5 
+ NH). MS (El, 70 ev) m/z (%): 337(M+, 100), 308 (6), 241 
(78.5), 214 (45), 189 (57), 118 (30.3), 96(18), 77 (64), 53 
(78). Anal. Calcd. for C18H15N3O2S (337.40): C, 64.08; H, 




White powder (AcOH), Yield (66 %), m.p. 221–222 ºC; IR 
(KBr) vmax/cm−1: 3316 (NH), 3061 (arom. CH), 2900 (aliph. 
CH), 2190 (C≡N), 1699 (C=O) and 1617 (C=O; amide); 1H 
NMR (DMSO-d6): δ/ppm: 2.09 (s, 3H, CH3), 2.30 (s, 3H, 
COCH3), 4.29 (d, 2H, CH2-NH, J = 6 Hz), 6.15 (d, 1H, furan-H3, 
J = 3 Hz), 6.34 (t, 1H, furan-H4, J = 3 Hz), 7.45-7.66 (m, 6H, 
Ar-H + furan-H5), 9.67 (t, 1H, O=C-NH-CH2, J = 6 Hz); 13C NMR 
(DMSO-d6) δ/ppm: 14.31 (CH3), 29.95 (COCH3), 36.10 (CH2), 
68.83 (C-CN), 103.52, 110.32, 141.59, 141.74 (furan-C), 
115.06, 145.35, 170.21 (thiazole-C), 128.90, 129.30, 129.77, 
131.23, 135.97 (ph-C), 152.80 (CN), 163.96, 165.22 (2C=O). 
MS (El, 70 ev) m/z (%): 379 (M+, 35), 350 (7), 283 (12.2), 265 
(9), 241 (7.5), 231 (15), 142 (4.3), 80 (100), 64 (85), 53 (10). 
Anal. Calcd. for C20H17N3O3S (379.43). C, 63.31; H, 4.52; N, 





White crystals (Dioxane), Yield (55 %), m.p. 231–232 ºC; IR 
(KBr) vmax/cm−1: 3410 (NH), 3066 (arom. CH), 2920 (aliph. 
CH), 2183 (C≡N), 1703 (C=O; ester) and 1633 (C=O; amide); 
1H NMR (DMSO-d6) δ/ppm: 1.29 (t, 3H, CH3, J = 6 Hz), 2.12 
(s, 3H, CH3), 3.45 (q, 2H, CH2, J = 6 Hz), 4.30 (d, 2H, CH2-NH, 
J = 6 Hz), 6.15 (d, 1H, furan-H3, J = 3.3 Hz), 6.35 (t, 1H, furan-
H4, J = 3.5 Hz), 7.44−7.62 (m, 7H, Ar-H + furan-H5 + NH). MS 
(El, 70 ev) m/z (%): 409 (M+, 100), 380 (7), 285 (47.5), 261 
(57), 212 (15), 169 (15.3), 118 (22), 77 (88), 53 (78). Anal. 
Calcd. for C21H19N3O4S (409.46): C, 61.60; H, 4.68; N, 10.26. 
Found: C, 61.50; H, 4.57; N, 10.17 %. 
2-Cyano-N-(furan-2-ylmethyl)-2-(4-(4-nitrophenyl)-3-
phenylthiazol-2(3H)ylidene)acetamide (12) 
Yellow powder (EtOH), Yield (60 %), m.p. 210−211 ºC; IR 
(KBr) vmax/ cm−1: 3336 (NH), 3080 (arom. CH), 2934 (aliph. 
CH), 2189 (C≡N) and 1637 (C=O; amide); 1H NMR (DMSO-d6) 
δ/ppm: 4.32 (d, 2H, CH2-NH, J = 6 Hz), 6.15 (d, 1H, furan-H3, 
J = 3.5 Hz), 6.35 (t, 1H, furan-H4, J = 3 Hz), 6.87(s, 1H, 
thiazole-H5), 7.09-8.19 (m, 11H, Ar-H + furan-H5 + NH). MS 
(El, 70 ev) m/z (%): 444(M+, 48), 364 (60), 321 (52.5), 302 
(37), 274 (39), 134 (5.3), 89 (15), 80 (82), 64 (100). Anal. 
Calcd. for C23H16N4O4S (444.46): C, 62.15; H, 3.63; N, 12.61. 





Beige crystals (AcOH), Yield (45 %), m.p. 285−286 ºC; IR (KBr) 
vmax/ cm−1: 3373 (NH), 3054 (arom. CH), 2932 (aliph. CH), 
2190 (C≡N), 1730 (C=O; thiazoldinone) and 1646 (C=O; 
amide); 1H NMR (DMSO-d6) δ/ppm: 4.10 (s, 2H, thiazole-
CH2), 4.17 (d, 2H, CH2-NH, J = 6 Hz), 6.08 (d, 1H, furan-H3, J 
= 3.5 Hz), 6.33 (t, 1H, furan-H4, J = 3 Hz), 7.26-8.18 (m, 11H, 
Ar-H + furan-H5), 9.75 (t, 1H, O=C-NH-CH2, J = 6 Hz); 13C NMR 
(DMSO-d6) δ/ppm: 31.65 (thiazole-CH2), 35.90 (CH2), 73.63 
(C-CN), 106.60 (thiazole-C5`), 110.35, 152.24, 153.23 (furan-
C), 113.90 (CN), 129.81, 129.92, 130.32, 133.86, 134.93 (Ar-
C), 161.99 (thiazole-C2), 163.63, 166.12 (thiazole-C4, C4`), 
173.30 (C=O). MS (El, 70 ev) m/z (%): 514(M+, 36), 434 (50.2), 
391 (21.5), 221 (78), 197 (68), 103 (43), 77 (100), 64 (40). 
Anal. Calcd. for C26H18N4O4S2 (514.58): C, 60.69; H, 3.53; N, 





Beige crystals (AcOH), Yield (45 %), m.p. 279−280 ºC; IR (KBr) 
vmax/cm−1: 3340 (NH), 3025 (arom. CH), 2910 (aliph. CH), 
2185 (C≡N), 1732 (C=O; thiazoldinone) and 1646 (C=O; 
amide); 1H NMR (DMSO-d6) δ/ppm: 1.03 (t, 3H, CH3, J = 6 Hz), 
2.04 (p, 2H, CH2, J = 6 Hz), 4.17 (d, 2H, CH2-NH, J = 6 Hz), 4.39 
(t, 1H, CH, J = 6 Hz), 6.08 (d, 1H, furan-H3, J = 3.3 Hz), 6.33 (t, 
1H, furan-H4, J = 3 Hz), 7.35-7.69 (m, 12H, Ar-H + furan-H5 + 
NH). MS (El, 70 ev): m/z (%) = 542 (M+, 25.5), 462 (23), 278 
(12.5), 249 (100), 234 (8), 179 (28), 147 (32), 103 (69), 77 
(100), 64 (34). Anal. Calcd. for C28H22N4O4S2 (542.63): C, 





To a solution of 7 (0.02 mol) in ethanol (30 mL), 
terephthalaldehyde (0.01 mol) and piperidine (0.5 mL) 
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h; the solid product which was produced on heating was 
collected and recrystallized from dioxane as red solid. Yield 
(45 %), m.p. 290−292 ºC; IR (KBr) vmax/cm−1: 3341 (br, NH), 
3028 (arom. CH), 2926 (aliph. CH), 2196 (C≡N), 1712 (C=O; 
thiazoldinone) and 1652 (C=O; amide); 1H NMR (DMSO-d6) 
δppm/ppm: 4.34 (d, 4H, 2CH2-NH, J = 6 Hz), 6.19 (d, 2H, 
furan-H3, J = 6 Hz), 6.36 (t, 2H, furan-H4, J = 6 Hz), 7.54 – 
8.11 (m, 16H, Ar-H + furan-H5), 8.35 (s, 2H, =CH), 10.06 (t, 
2H, 2 O=C-NH-CH2, J = 6 Hz). MS (El, 70 ev) m/z (%): 776 (M+, 
28.6), 662 (8), 501 (12.5), 439 (7.3), 385 (12), 242 (8), 149 
(13), 85 (45), 71 (73), 57 (100). Anal. Calcd. for C42H28N6O6S2 
(776.84): C, 64.94; H, 3.63; N, 10.82. Found: C, 64.72; H, 





A mixture of 7 (0.01 mol), chalcone 21 (0.01 mol) and 
piperidine (0.5mL) in ethanol (30 mL) was heated under 
reflux for 3 h; the solid product which was produced on 
heating was collected and recrystallized from dioxane as 
yellow solid, Yield (40 %), m.p. 228-230 ºC; IR (KBr) 
vmax/cm−1: 3431 (br, NH), 3022 (arom. CH), 2956 (aliph. CH), 
2205 (C≡N), and 1651 (C=O; amide); 1H NMR (DMSO-d6) 
δ/ppm: 3.43, 4.93 (2d, 2H, pyran-H4,H5, J = 6 Hz), 3.84 (s, 
3H, OCH3), 4.32 (d, 2H, CH2-NH, J = 6 Hz), 6.09 (d, 1H, furan-
H3, J = 6 Hz), 6.30 (t, 1H, furan-H4, J = 3 Hz), 6.85 - 7.47 (m, 
16H, Ar-H + furan-H5), 8.20 (t, 1H, O=C-NH-CH2, J = 6 Hz). 
MS (El, 70 ev) m/z (%): 559 (M+, 37.6), 502 (6), 435 (60.5), 
392 (12), 313 (5), 217 (6), 105 (13), 84 (100), 81 (84), 57 
(87). Anal. Calcd. for C33H25N3O4S (559.63): C, 70.82; H, 
4.50; N, 7.51. Found: C, 70.97; H, 4.36; N, 7.45 %. 
General Procedure for the Preparation 
of Compounds 23a and 23b: 
Method A: A mixture of 7 (0.01 mol), α-cinnamonitrile 20 
(0.01 mol) and piperidine (0.5mL) in ethanol (30 mL) was 
heated under reflux for 1h; the solid product which 
produced on heating was collected and recrystallized from 
the proper solvent to give 23. 
Method B: A mixture of compound 7 (0.02 mol), aromatic 
aldehyde (0.01 mol) and piperidine (0.01mol) in ethanol (30 
mL) was heated under reflux for 1 h; the solid product 
which was produced on heating was collected and 




Orange powder (AcOH), Yield (50 %), m.p. 268−270 ºC; IR 
(KBr) vmax/ cm−1: 3325 (NH), 3060 (arom. CH), 2921 (aliph. 
CH), 2206 (C≡N), 1717 (C=O; thiazoldinone) and 1647 (C=O; 
amide); 1H NMR (DMSO-d6): δ/ppm: 4.31 (d, 2H, CH2-NH, J 
= 6 Hz), 6.19 (d, 1H, furan-H3, J = 3 Hz), 6.35 (t, 1H, furan-
H4, J = 3 Hz), 7.55 - 7.80 (m, 10H, + Ar-H + furan-H5), 7.89 
(s, 1H, =CH), 8.28 (t, 1H, O=C-NH-CH2, J = 6 Hz). MS (El, 70 
ev) m/z (%): 461 (M+, 8.10), 426 (50.6), 364 (15.5), 303 (22), 
265 (19.5), 168 (88), 96 (90), 77 (100), 64 (43). Anal. Calcd. 
for C24H16ClN3O3S (461.92): C, 62.41; H, 3.49; N, 9.10. 




Orange powder (AcOH), Yield (52 %), m.p. 265−266 ºC; IR 
(KBr) vmax/cm−1: 3332 (NH), 3058 (arom. CH), 2921 (aliph. 
CH), 2205 (C≡N), 1714 (C=O; thiazoldinone) and 1647 (C=O; 
amide); 1H NMR (DMSO-d6): δ/ppm: 4.31 (d, 2H, CH2-NH, J 
= 6 Hz), 6.21 (d, 1H, furan-H3, J = 6 Hz), 6.36 (t, 1H, furan-
H4, J = 3 Hz), 7.24 - 7.54 (m, 10H, + Ar-H + furan-H5), 8.11 
(s, 1H, =CH), 12.26 (t, 1H, O=C-NH-CH2, J = 6 Hz). MS (El, 70 
ev) m/z (%): 506 (M+, 62.5), 507 (M+1, 61.5), 426 (30.6), 364 
(29.5), 303 (22), 265 (19.5), 212 (30), 133 (44), 96 (93), 77 
(100), 53 (61). Anal. Calcd. for C24H16N3BrO3S (506.37): C, 
56.93; H, 3.18; N, 8.30. Found: C, 56.70; H, 3.00; N, 8.10 %. 
Antimicrobial Screening 
The disks of Whatman filter paper were prepared with 
standard size (6.0 mm diameter) and kept into 1.0 Oz screw 
capped wide mouthed containers for sterilization. These 
bottles are kept into hot air oven at a temperature of 150 
ºC. Then, the standard sterilized filter paper disks 
impregnated with a solution of the test compound in DMF 
(100 µL, 5 mg/mL) were placed on nutrient agar plate 
seeded with the appropriate test organism in triplicates. 
Standard concentrations of 106 CFU/mL (Colony Forming 
Units/mL) and 104 CFU/mL were used for antibacterial and 
antifungal assay, respectively. Pyrex glass Petri dishes (9 cm 
in diameter) were used and two disks of filter paper were 
inoculated in each plate. The utilized test organisms were 
S. aureus, S. epidermidis and B. subitilis as examples of 
Gram-positive bacteria and P. aeruginosa, P. vulgaris and K. 
pneumonia as examples of Gram-negative bacteria. They 
were also evaluated for their in vitro antifungal potential 
against A. fumigatus, A. clavatus and G. candidium fungal 
strain. Ampicillin and gentamycin were used as standard 
antibacterial agents; while amphotericin B was used as 
standard antifungal agent. DMF alone was used as control 
at the same above-mentioned concentration and due this 
there was no visible change in bacterial growth. The plates 
were incubated at 37 ºC for 24 h for bacteria and for 48 h 
at 25 ºC for fungi. The mean zone of inhibition measured in 
mm ± standard deviation beyond well diameter (6 mm) 
produced on a range of environmental and clinically 
pathogenic microorganisms. Compounds that showed 
significant growth inhibition zones using the twofold serial 
dilution technique were further evaluated for their minimal 
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Minimal Inhibitory Concentration (MIC) 
Measurement 
The microdilution susceptibility test in Müller-Hinton 
Broth (Oxoid) and Subouraud Liquid Medium (Oxoid) was 
used for the determination of antibacterial and antifungal 
activity, respectively. Stock solutions of the tested 
compounds, ampicillin, gentamycin, amphotericin B and 
sulfisoxazole were prepared in DMF at concentrations 
1000 µg/mL. Each stock solution was diluted with standard 
method broth (Difco) to prepare serial twofold dilutions in 
the range of 500-0.007 µg/mL. 10 mL of the broth 
containing about 106 CFU/mL of test bacteria or 104 
CFU/mL of the test fungus was added to each well of 96-
well microtiter plate. The sealed microplates were 
incubated at 37 ºC for 24 h for antibacterial activity and at 
25 ºC for 48 h for antifungal activity in a humid chamber. 
At the end of the incubation period, the minimal inhibitory 
concentrations (MIC) values were recorded as the lowest 
concentrations of the substance that had no visible 
turbidity. Control experiments with DMF and uninoculated 
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